Summit Therapeutics
SMMT
123 hedge funds and large institutions have $563M invested in Summit Therapeutics in 2024 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 20 increasing their positions, 47 reducing their positions, and 21 closing their positions.
174% more capital invested
Capital invested by funds: $205M → $563M (+$358M)
95% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 21
53% more call options, than puts
Call options by funds: $13.8M | Put options by funds: $9.02M
17% more funds holding
Funds holding: 105 → 123 (+18)
3.22% more ownership
Funds ownership: 7.06% → 10.28% (+3.2%)
57% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$125M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.9M |
| 3 |
Millennium Management
New York
|
+$10.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.37M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$21.6M |
| 2 |
BlackRock
New York
|
-$10.4M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2.72M |
| 4 |
Citigroup
New York
|
-$2.68M |
| 5 |
Rafferty Asset Management
New York
|
-$2.62M |
SMMT Hedge Fund Activity: Q2 2024 in Review
123 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2024, worth a combined $563M — up 174% from $205M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new SMMT positions and 21 closed out — a net gain of 20 holders — while 20 added to existing stakes and 47 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $125M. The largest seller was State Street, cutting an estimated $21.6M.
- 123 institutional investors held Summit Therapeutics (SMMT) as of Q2 2024, up from 105 in Q1 2024.
- Funds reported $563M of Summit Therapeutics stock for Q2 2024, up 174% quarter-over-quarter.
- 41 funds opened new Summit Therapeutics positions in Q2 2024 and 21 closed out, a net change of +20 holders.
- The largest Summit Therapeutics buyer in Q2 2024 was Baker Bros. Advisors, an estimated $125M added.
- The largest Summit Therapeutics seller in Q2 2024 was State Street, an estimated $21.6M sold.
Based on aggregated 13F filings for Q2 2024.